COMP360

Product

Last mentioned: Mar 24, 2026

Timeline

  1. Anticipated Data Readout

    Expected primary endpoint results for the COMP005 Phase 3 trial in TRD.

  2. Fiscal Year End

    Closed 2025 with a strategic focus on regulatory filing preparations.

  3. Therapist Training Milestone

    Completed training for over 500 facilitators to support Phase 3 delivery protocols.

  4. Phase 3 Expansion

    Compass increased the number of active clinical sites for COMP006 to over 50 globally.

Stories mentioning COMP360 1

market-trends Neutral

Compass Pathways Reports 2025 Results as Pivotal Phase 3 Data Looms

Compass Pathways reported its full-year 2025 financial results, highlighting a strategic focus on its pivotal Phase 3 COMP360 program for treatment-resistant depression. With a cash runway extending into late 2026, the company is positioned for a critical year of clinical readouts and regulatory engagement.

2 sources